Stem Cells by Negmetzhanov, Baurzhan & Shuttari, Shaaz Hijaz
Worcester Polytechnic Institute
Digital WPI
Interactive Qualifying Projects (All Years) Interactive Qualifying Projects
October 2009
Stem Cells
Baurzhan Negmetzhanov
Worcester Polytechnic Institute
Shaaz Hijaz Shuttari
Worcester Polytechnic Institute
Follow this and additional works at: https://digitalcommons.wpi.edu/iqp-all
This Unrestricted is brought to you for free and open access by the Interactive Qualifying Projects at Digital WPI. It has been accepted for inclusion in
Interactive Qualifying Projects (All Years) by an authorized administrator of Digital WPI. For more information, please contact digitalwpi@wpi.edu.
Repository Citation
Negmetzhanov, B., & Shuttari, S. H. (2009). Stem Cells. Retrieved from https://digitalcommons.wpi.edu/iqp-all/1950
IQP-43-DSA-5349 
IQP-43-DSA-6580 
 
 
 
 
STEM CELLS AND SOCIETY 
 
 
 
 
An Interactive Qualifying Project Report 
 
Submitted to the Faculty of 
 
WORCESTER POLYTECHNIC INSTITUTE 
 
In partial fulfillment of the requirements for the 
 
Degree of Bachelor of Science 
 
By: 
 
 
 
 
_________________________               _________________________ 
                          Baurzhan Negmetzhanov                                Shaaz Shuttari 
 
 
October 26, 2009 
 
 
 
 
 
 
APPROVED: 
 
 
_________________________ 
Prof. David S. Adams, Ph.D. 
Project Advisor 
 2 
ABSTRACT 
 
 
  
The purpose of this project is to describe the impact of stem cells on society by 
describing their types, how they are isolated, and their medical benefits, while also investigating 
the ethical and legal issues surrounding their use.  Chapter-1 and Chapter-2 describe different 
types of stem cells and their sources, and explain various applications of stem cells and how they 
can contribute to treating different diseases.  Chapter-3 and Chapter-4 discuss ethical issues 
surrounding stem research, and the laws that govern their use.  Based on the project research, the 
authors provide conclusions about the future directions of stem cell research. 
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PROJECT OBJECTIVES 
 
  
 The objective of this IQP is to discuss and research the topic of stem cells, and examine the 
effects of this technology upon society.  The purpose of chapter-1 is to describe the various types 
and sources stem cells, their functions and properties, how stem cells are isolated from their 
sources, and explain the levels of potency.  Chapter-2‟s purpose is to document the use of stem 
cells to treat different diseases, in both animal experiments and human clinical trials.  Chapter-
3‟s purpose is to address the different ethical issues facing the use of stem cells, and explain 
various reasons why people support or do not support stem cell research.  Chapter-4‟s purpose is 
to describe various domestic and international laws governing the use of stem cells, and discuss 
future legislation that will strongly stem cell research.  Finally, an overall conclusion will be 
generated by both IQP authors discussing the future implementation of stem cells, and which 
stem cell laws each author agrees with the most. 
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Chapter-1:  Stem Cell Introduction: 
Types and Sources 
 
Shaaz Shuttari 
 
 
 When one talks about stem cells, one delves into a subject full of amazing promise to the 
human race that‟s also filled with controversy.  Stem cells are described as the body‟s master 
cells that have a long life span and can differentiate into other cell types to perform various 
functions (American Federation, 2003).  Under ideal conditions in the body or a laboratory, stem 
cells divide to form more daughter stem cells (Mayo Clinic, 2006).  The newly formed daughter 
cells can turn into specialized cells with a specific function, such as bone, blood, or brain cells 
(Mayo Clinic, 2006).  Daughter cells can also self-renew to form new stem cells (Mayo Clinic, 
2006).  Stem cells are highly unique from any other type of cell because no other cell in the 
human body can self-renew and differentiate.  Because of these regenerative properties, stem 
cells have become the central focus of the new field of regenerative medicine.  Researchers are 
interested in the study of stem cells, with the hope of solving some of humanities worst health 
problems, increasing our knowledge of a disease, testing new drugs for safety and effectiveness, 
and generating healthy cells that can replace diseased ones. 
 Some types of stem cells are obtained by destroying embryos, which some believe is 
murder and others believe is a miracle.  The topic of attaining stem cells from embryos is highly 
controversial.  But not all types of stem cells destroy embryos during their production, and these 
cells are not as controversial.  The purpose of this chapter is to document the various types of 
stem cells, and to focus on their relative strengths and weaknesses for medical purposes, as a 
basis for subsequent chapters on stem cell ethics and legalities. 
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Stem Cell Types  
 Stem cells can predominately be divided into three main types: embryonic stem (ES) cells 
that are isolated from an embryo, adult stem cells that are isolated from various adult cells, and 
induced stem cells that are induced to form from adult fibroblast cells.  ES cells are sometimes 
referred to as “unlimited stem cells” since they are immortal, while adult stem cells are termed 
“limited stem cells” (ISSCR, 2006).  ES cells are usually isolated from the inner cell mass of a 
five-day-old blastocyst embryo obtained from an in vitro fertilization (IVF).  Adult stem cells 
can be obtained from the umbilical cord blood and various tissues within the adult human body, 
such as in bone marrow, brain, and skin (Yu and Thomson, 2006).    
Stem cells can also be categorized by their potentials.  Totipotent cells are newly 
fertilized eggs that can form any type of cell, through the eight-cell stage.  Pluripotent cells can 
form any cell of the adult organism, but not extra-embryonic tissue such as the placenta.  
Multipotent cells can form into several types of related cells.  Unipotent cells can mostly form 
into one other type of cell.   Stem cells can be grown in a lab with highly specialized incubators, 
without changing their composition until enough are grown for therapy (Scott, 2007).   
 
Embryonic Stem Cells 
ES cells are among the most pluripotent type of stem cell, meaning they have the ability 
to develop into numerous cell types of the body (ISSCR, 2006). These cells are obtained from an 
embryo that has undergone in vitro fertilization (IVF) outside a living organism in a controlled 
environment (Bellomo, 2006).  When fertilization occurs, a sperm head containing a nucleus 
enters the egg and its tail is cut off and left behind (Bellomo, 2006).  The embryo begins 
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dividing, and after five days a hollow ball of cells forms as a blastocyst (Bellomo, 2006).  The 
blastocyst is made up of two cell types, an inner layer of a cluster of cells known as the inner cell 
mass which develops into an embryo, and an outer layer referred as the trophoblast which forms 
the placenta (Bellomo, 2006).  Embryonic stem cells are found in the inner cell mass of the 
blastocyst (Bellomo, 2006).  ES cells have the greatest medical potential of all the stem cell types 
due to their pluripotency.  Because an embryo is usually destroyed to obtain ES cells, they are 
also the most ethically controversial. 
 Generally researchers collect ES cells using a pipette and transfer them to a Petri dish for 
culturing (Bellomo, 2006).  Numerous colonies form in the Petri dishes and are transferred into 
new Petri dishes.  Depending on the culture conditions, the ES cells either self-renew or 
differentiate.  Added signaling molecules can lead towards differentiation into a specific type of 
cell, such as nerve, bone, cardiac, and pancreatic cells (Bellomo, 2006).  From these newly 
created cells, cell replacement therapy can be used to replace tissues and restore their functions 
(Bellomo, 2006).   
   During ES cell transplantation experiments in mice, to reduce the risk of immuno-
rejection of the transplant, a technique termed somatic cell nuclear transfer (SCNT) has been 
devised to produce ES cells with the same genetic traits as the donor.  This technique when 
applied to human patients should eventually revolutionize medicine.  This technique works 
through removal of the nucleus from a donor egg (Bellomo, 2006).  A biopsy is then taken from 
the patient in need, for example skin cells, and a nucleus from one of the donor cells is 
transferred into the enucleated donor egg (Bellomo, 2006).  The egg is then cultured in vitro to 
the blastocyst stage from which ES cells gentically identical to the donor are obtained (Bellomo, 
2006).  Though SCNT has been used on mice and cattle to produce stem cells, the cloning of 
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human embryos using somatic donor cells has been problematic and has not yet been reported by 
any researcher (Cibelli et al, 2001).  Scientists feel that SCNT in humans would be unsafe and is 
ethically questionable (Cibelli et al, 2001).  Beyond therapeutic cloning, there has been a mutual 
agreement among most scientists and physicians that any type of reproductive cloning in humans 
should be banned (Michigan Citizens….2006). 
 Although stem cell applications are the subject of Chapter-2, one medical application that 
ES cells may help in is spinal cord trauma.  The process of repairing a damaged spinal cord is 
very difficult because the destroyed neurons must be replaced by neurons that make proper 
connections, and the newly placed neurons must be insulated with myelin (Transplantation of 
Neural Stem Cells….2003).  Thus stem cell researchers trying to repair damaged spinal cords 
must create stem cells that become neurons to restore the neural circuit and oligodendrocytes to 
produce myelin insulation.  Dr. Ronald McKay, a stem cell researcher at the National Institute of 
Health, has shown that mouse ES cells can repair neural damage when injected into rats 
(Transplantation of Neural Stem Cells….2003).  A team of researchers at the Washington 
University School of Medicine has been able to successfully differentiate mouse ES cells into 
oligodendrocytes to remylenate axons in vitro (Transplantation of Neural Stem Cells into the 
Spinal Cord, 2003). 
 
Adult Stem Cells 
 The second main class of stem cells are adult stem cells (ASCs).  ASCs are much harder to 
extract from the human body because they are relatively rare compared to the surrounding 
differentiated cells, but they have the potential to be more widely used in medicine due to less 
ethical issues of how they are extracted versus ES cells.  Adult stem cells have been identified in 
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many organs and tissues, including brain, bone marrow, peripheral blood, umbilical cord blood, 
blood vessels, skeletal muscle, skin, teeth, heart, gut, liver, ovarian epithelium, and testis (Scott, 
2007).  ASCs are thought to reside in a specific area of each tissue, called a "stem cell niche" that 
serves to aid their survival (Scott, 2007).  ASCs, also referred as limited stem cells, are rare cells 
that can be found only in certain organs and tissues, but not in all (ISSCR, 2006).  These limited 
cells can only be used in repairing the types of tissues and organs that they came from, e.g. skin 
adult stem cells can only be used to repair the skin and no other organ or tissue, and not every 
organ or tissue has been found to have them, making them difficult to obtain.    
Once stem cells are injected into the body, some have the ability to home in on their 
tissue of origin, while others do not.  Undifferentiated ES cells lack homing potential, while 
differentiated ES cells, or adult stem cells, have this homing potential (Bellomo, 2006).  ES cells 
typically form teratomas in various parts of the body, and start to associate with one another, 
while adult stem cells are differentiated enough to find the specific tissue or organ that they 
derive from.  For example, injected hematopoietic stem cells will return to the bone marrow.   
One of the most abundant sources for ASCs is the placenta of a developing fetus.  It has 
up to ten times as many stem cells as the blood of an umbilical cord, and the latter has 10 times 
more than bone marrow (The Stem Cell Debate, 2001).  Overall, the odds of identifying and 
finding an ASC is small since only one cell in 100,000 is an ASC (The Stem Cell Debate, 2001). 
 The process of differentiation helps convert ASCs or progenitor cells into more specialized 
cells that can be used to replace cells in the specific organ or tissue that they came from (Scott, 
2007).  ASCs can either be differentiated in vivo after the cells are injected, or can be 
differentiated in vitro by growth in the presence of various growth factors (Scott, 2007).  For 
example, when producing neurons or epithelial cells, scientists will select specific growth factors 
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such as nerve growth factor (NGF) and epidermal growth factor (EGF), which both contribute to 
generate the production of these cells in vivo (Scott, 2007).  This procedure requires a lot of 
experimentation.  Compounds known to bring about specific types of gene expression will be 
tested for inducing differentiation, and existing differentiation will also be tested (Scott, 2007).  
In a way, scientists are coming up with an index of culture additives that can lead to production 
of specific cell types.  Directed differentiation may also help scientists understand the molecular 
nature of plasticity and specific factors that distinguish adult and embryonic stem cells.  
One of the best-characterized types of ASC is the hematopoietic stem cell (HSC).  These 
cells are usually obtained from bone marrow, but are more frequently found in umbilical cord 
blood.  In a common procedure to treat leukemia, HSCs are obtained from a bone marrow tap of 
a donor then perfused into a patient who previously had radiation or chemotherapy to destroy 
their own bone marrow.  If the graft grows, the donor cells colonize the patient‟s bone marrow to 
begin producing various cellular components of blood.  A future adaptation of this procedure 
may allow HSCs to be differentiated in vitro to change the cells into another type of tissue prior 
to infusion (Mayo Clinic, 2006).   This potential is termed plasticity or trans-differentiation, to 
denote the process of changing into a cell type different than its origins.  This application could 
remove the ethical problems with obtaining embryos.  If cells were obtained from the same 
patient it would solve problems related to immunorejection (Mayo Clinic, 2006).  The cost of 
this procedure would not likely exceed a standard bone marrow transplant, but might take longer 
to preform since the cells need to be transdifferentiated (Mayo Clinic, 2006).  
Dr. Catherine Verfaille and her associates at the University of Minnesota have studied the 
transdifferentiation process.  This team showed that stem cells isolated from adult bone marrow 
might have the plasticity equivalent to ES cells (University of Minnesota, 2002).  They isolated 
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mouse bone marrow cells and differentiated them in vitro into cell types representing the three 
essential germ layers, which are the endoderm, mesoderm, and neuroectoderm (University of 
Minnesota, 2002).  When injected into a mouse, the cells were able to contribute to most types of 
somatic cells.  The application of this stem cell procedure could prove effective for 
implementing stem cell therapy in patients, especially for repairing simpler types of tissues such 
as liver or bone marrow (University of Minnesota, 2002). 
 
Different Types of Adult Stem Cells 
 There are many types of adult stem cells that come from numerous locations of the body.  
Adult hematopoetic stem cells (HSCs) come from bone marrow, and form into different types of 
blood cells, and they can provide protection for fighting various infections.  Adult neuronal stem 
cells (NSCs) form from the brain, and give rise to three major cell types as neurons, astrocytes, 
or oligodendrocytes.  Adult cardiac stem cells (CSCs) come from the heart and can provide 
cardiac repair in damaged tissue such as from a heart attack.  Adult epithelial stem cells come 
from the lining of the digestive track, and can give rise to different cell types, such as goblet and 
enteroendocrine cells that can replace cancerous ones.  Mesenchymal stem cells (MSCs) are 
found in bone marrow, and can form into a variety of cells, such as nerve and muscle cells.  
Adult intestinal stem cells come from the villi and crypts of the intestine, and have the ability to 
divide rapidly on a daily basis.  Adult eye stem cells are mainly found in the retina, and  can 
work towards curing blindness.  Parthenotes can be used as a source of embryonic stem cells, 
which result from parthenogenesis or “virgin birth,” which can turn human eggs into “embryo-
like balls” using embryos that can never develop into human beings (Brevini and Gandolfi, 
2007). 
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Adult Hematopoietic Stem Cells 
 In the history of stem cell research, adult hematopoietic stem cells (HSCs) have been used 
successfully in therapies for decades.  These stem cells turn into different types of blood cells, 
and are very easy to obtain for research.  They can be used to treat multiple types of leukemias, 
sickle-cell diseases, multiple myelomas, or cancer of plasma cells.  In 2006, there were fifty 
thousand successful transplants of HSCs worldwide (Medscape, 2008). 
 There are two classes of transplant HSCs: autologous and allogeneic.  Autologous 
transplants use HSCs that were removed from the same patient before cancer treatment 
(Medscape, 2008).  Allogeneic transplants involve HSCs removed from another person 
(Medscape, 2008).  Blood from the umbilical cord of a placenta is one of the richest sources of 
HSCs (Medscape, 2008). 
 HSCs are critically important in the production of all types of blood cells, such as red 
blood cells, lymphocytes, neutrophils, and macrophages.  These stem cells have the ability to 
self-renew and are multipotent (Medscape, 2008).  HSCs have been used in bone marrow 
transplants for decades to treat leukemia and other diseases of the spinal cord or blood 
(Medscape, 2008). 
 
Adult Neuronal Stem Cells  
 The existence of neuronal stem cells (NSCs) was found during neurogenesis, which leads 
to the creation of new neurons.  These stem cells can grow into new brain cells in two areas of 
the brain, the olfactory bulb where odor is processed, and the dentate gyrus in the central part of 
the hippocampus for memory and learning (Rebuilding the Nervous System with Stem Cells, 
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2005).  When these stem cells divide, they must choose either to remain a NSC, turn into a nerve 
cell, or convert into astrocytes that hold neurons in place or oligodendrocytes that are hair-like 
extensions that send signals from one neuron to the next (Rebuilding the Nervous System with 
Stem Cells, 2005).  In a petri dish these stem cells can differentiate into any type of brain cell, 
however when these stem cells are placed in their natural environment they typically become 
neurons (Rebuilding the Nervous System with Stem Cells, 2005).  NSCs have been known to 
have beneficial effects with patients with Parkinson's or Alzheimer‟s disease, through their 
potential to grow back dead tissue and restore function in neural regions. 
 
Adult Cardiac Stem Cells 
 Adult cardiac stem cells (CSCs) are found in the heart, and are beginning to be used to treat 
heart disease.  Bone marrow resident CSCs are usually induced by a variety of growth factors to 
differentiate into specialized cells called Angiogenic Cell Precursors (ACPs) (Touchette, 2004).  
Plaque build up in an artery can lead to a reduction in the volume of blood being pumped in and 
out of the artery to the heart.  ACPs are then attracted to this ischemic area by growth factors, 
and then travel through the vessel wall into damaged tissue (Touchette, 2004).  This action helps 
form new blood vessels and repair any damaged tissue.  For this treatment, more ACPs are 
sometimes grown and placed back into the body through a regular cauterization (Touchette, 
2004).  From this cauterization, ACPs will be able to differentiate into endothelial cells that lead 
to the formation of new blood vessels and help ease symptoms for patients with severe heart 
problems (Touchette, 2004).  There are a lot of positive cases of regeneration of new cells in 
damaged tissue using cardiac stem cells (Touchette, 2004). 
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Mesenchymal Stem Cells 
 Used highly in regenerative medicine, mesenchymal stem cells (MSCs) are multipotent 
cells capable of differentiating into cells of mesodermal origin (Jackson et al., 2007).  These 
multipotent stem cells form in bone marrow.  In lab conditions, MSCs are grown into a variety of 
cells such as tendon, ligament, bone, and cartilage (Jackson et al., 2007).  Fortunately, substantial 
knowledge exists on how to grow these stem cells in culture.  These stem cells have been 
approved for use in clinical trials, and have beneficial effects for tissue repair (Jackson et al., 
2007).  These stem cells are easy to culture for differentiation into different cell types, which can 
lead scientists to make strides in understanding their molecular pathways.  These stem cells also 
can take up and maintain introduced genes in a process that could be used to deliver helpful 
molecules to targeted locations (Jackson et al., 2007). 
 An important application of MSCs is their use in human trials where they are derived from 
a small bone marrow sample in a patient, and then grown in culture and given back to the same  
patient (Jackson et al., 2007).  This autologous application could be used to solve problems 
associated with immune rejection of foreign cells and tissues (Jackson et al., 2007).  These stem 
cells have proven beneficial in patients with arthritis. 
 
Adult Epithelial Cells 
 Adult epithelial stem cells (ESCs) come from the lining in the digestive track.  In adult 
self-renewing tissue such as the skin, ESCs are thought to maintain regular tissue homeostasis 
and can act as a reserve for tissue replacement (Harvard Medical School, 2007).  These stem 
cells have a relatively long life span, and are normally tagged as label-retaining cells (LRC) 
(Harvard Medical School, 2007).  Label retention has been used to identify somatic stem cells 
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and locate their location within the stem cell niche (Harvard Medical School, 2007).  Although 
label-retaining cells rarely grow at rapid rates, they have a high proliferation potential when 
tissue expands, such as during wound healing (Harvard Medical School, 2007).  Researchers 
have found that cutaneous tumors can arise from these stem cells, thus targeting these stem cells 
can be important for the study of carcinogenesis. 
 The p63 gene has been known to be “the master regulator of epithelial stem cells” (P63 and 
The Epithelial Stem Cell: More Than Status Quo?, 2004).  Researchers have found that mice 
mutated in p63 run out of regenerative epithelial stem cells (P63 and The Epithelial Stem Cell: 
More Than Status Quo?, 2004).  This study, led by Frank McKeon of Harvard Medical School, 
shows that p63‟s role is not involved with tissue differentiation, but instead helps “stemness” or 
renewal to occur in regenerative cells in tissues (P63 and The Epithelial Stem Cell: More Than 
Status Quo?, 2004).  McKeon and his team used ESCs as a method to show that p63‟s key role 
was to make potential stem cells divide (P63 and The Epithelial Stem Cell: More Than Status 
Quo?, 2004).  As McKeon commented about his p63 research, “dissecting genetic programs 
controlled by certain regulators will tell us much about how stem cells normally function, and 
how control goes away in cancer” (Harvard Medical School, 2007).  This research shows that 
epithelial stem cell research can greatly help in the treatment of cancer in the skin, prostate, and 
breast.           
 
Adult Intestinal Stem Cells 
 Adult intestinal stem cells come from the villus and crypt areas of the intestine.  Scientists 
found that the transcription factor Achaetescute-like2 (Ascl2) turns on a stem cell-creating 
program in intestinal cells (Barker et al., 2007).  When the Ascl2 gene turns on, any dividing cell 
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in the intestine turns into a stem cell that is able to produce any other cell type in that tissue 
(Barker et al., 2007).  Crypts are the main location of stem cells, and Paneth cells protect these 
stem cells (Barker et al., 2007).  Every five days the intestinal lining is completely replaced by 
the remaining stem cells and their Paneth cell defenders (Barker et al., 2007).   
 As Han Clevers of Hubrecht Institute in The Netherlands explained about intestinal stem 
cells, “these stem cells can produce 200-300 grams of new cells daily” (The Making of An 
Intestinal Stem Cell, 2009).  Clevers and his team found that tiny cells within the Paneth region 
of the intestine have stem cell like features (The Making of An Intestinal Stem Cell, 2009).  
These cells are derived from the expression of gene Lgr5 (Barker et al., 2007).  When Clevers 
and his team induced Ascl2 transcription factor in the intestinal lining of a mouse, it caused 
crypts to overgrow and develop within villi (The Making of An Intestinal Stem Cell, 2009).  
Clevers‟s research showed that adult mouse intestines lacking Ascl2 will cause the Lgr5 stem 
cells to stop developing (The Making of An Intestinal Stem Cell, 2009).  Thus Ascl2 is the key 
factor to the overall status of an intestinal stem cell.  These stem cells can help in the treatment of 
colon cancer and various types of GI infection. 
 
Adult Eye Stem Cells 
 Adult eye stem cells isolated from the eye were initially believed to be retinal cells, but 
researchers at St. Jude Children‟s Hospital found these cells were actually adult stem cells 
(Reuters, 2001).  Retinal stem cells could help provide treatments for those suffering from retinal 
degeneration (Reuters, 2001).  The goal is to re-engineer stem cells into light-sensitive 
photoreceptor cells to treat retinal degeneration. 
 A team led by Dr. Michael Dyer, researcher at St. Jude Children‟s Hospital, proposed that 
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a layer of ciliary epithelial cells lining the inside of the eye contains retinal stem cells that, when 
grown in culture, produce tiny spheres of a thousand cells (Reuters, 2001).  These tiny spheres 
could self-renew, and can be cultured to produce more spheres (Reuters, 2001).  These new 
spheres have gene traits similar to adult eye cells, which were found by culturing these sphere-
forming cells in the same growth area used for stem cells (Reuters, 2001).  Dyer‟s continuing 
research involves taking samples of adult cells from patients with retinal degeneration and uses 
genetic factors to revert these cells into stem cells (Reuters, 2001).  These cells are considered 
iPS cells (see below) and can be configured to grow into light-sensing photoreceptor cells for 
transplantation in a patient‟s eyes to restore vision (Reuters, 2001).  These stem cells may prove 
beneficial for people with blindness or any type of visual impairment. 
 
Parthenotes 
 Parthenotes do not face the same ethical, religious, and legal issues that embryonic stem 
cells face.  A parthenote embryo does not develop beyond the early fetus stage, and can never 
grow into a human being (Brevini and Gandolfi, 2007).  As an alternate source for pluripotent 
cell lines, artificial parthenogenesis can be used to create parthenotes that make desired 
pluripotent cell lines.  In “virgin birth” or parthenogenesis, an unfertilized egg retains both sets 
of chromosomes and begins to develop (Brevini and Gandolfi, 2007).  This egg usually dies 
within a few days, however stem cells can be extracted if they can live to the blastocyst stage, 
usually 5 days  (Brevini and Gandolfi, 2007). 
 Parthenote ES cells have been derived from mice and monkeys, but not yet man.  The most 
successful results have been found in monkey eggs, where cell lines have been growing for over 
two years (Brevini and Gandolfi, 2007).  Analysis of the monkey parthenote ES cells shows that 
 18 
they are impossible to differentiate from embryonic stem cells derived from fertilized eggs 
(Brevini and Gandolfi, 2007).  Further research is needed to confirm that tissues derived from 
parthenogenetic stem cells are fully functional.  Jerry Hall of the Institute for Reproductive 
Medicine and Genetics in Los Angeles is hopeful in saying, “patients are so interested in this 
procedure, and we are confident enough in its feasibility that we have been willing to store eggs 
for use as soon as safety and effectiveness is shown” (Carpenter, 2008). 
 The use of parthenogenetic stem cells can not be used for obtaining autologous stem cells 
for men, or from women after menopause, however using therapeutic cloning (discussed below) 
could achieve results for any patient (Brevini and Gandolfi, 2007).  In the future, banks for 
parthenogenetic stem cells could provide cells for patients in need.  The hope is to use 
differentiated cells derived in vitro by parthenogenesis to eliminate the need to produce or 
disassemble a normal fertilized embryo.  This would avoid most ethical issues in the use of 
parthenotes (except for those associated with normal egg donations) and may provide a positive 
impact for the development of stem cell research. 
              
Induced Pluripotent Stem Cells 
One of the most exciting findings in stem cell research of the past decade is the 
development of a technique for producing ES-like cells from adult skin fibroblast cells.  This 
technique does not destroy an embryo, so in theory could provide ES-like cells for therapy 
without strong ethical concerns.  And moreover, the ES-like cells would be genetically identical 
to the patient.  These cells are termed induced pluripotent stem cells (iPS), also termed induced 
embryonic stem cells (iES).  In this technique, skin fibroblast cells are isolated and transfected 
with plasmid DNAs encoding various key transcription factors that activate the fibroblast cells to 
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de-differentiate to a stem like state (Bellomo, 2006).  iPS cells are similar to ES cells due to their 
pluripotent capacity to become almost any type of cell (Bellomo, 2006).  Of the four ways to 
obtain a pluripotent stem cell, ES, SCNT, parthenote, and induced, all except the induced 
technique require an embryo (Bellomo, 2006).  This induced method has caused a lot of 
excitement around the scientific community.   
iPS cells were first produced from mouse fibroblast cells in 2006 using plasmids to 
encode six pluripotency-inducing transcription factors, Sox-2, Oct-4, c-Myc, Nanog, Lin28, and 
Klf4 (Takahashi et al., 2007).  Following transfection, after a few short weeks, some of the cells 
turned into pluripotent cells with characteristics of ES cell lines (Takahashi et al., 2007).  The 
iPS cells showed several important traits of pluripotent stem cells, including the formation of all 
three germ layers, and their ability to aid in growth of various tissues when injected in mouse 
embryos (Takahashi et al., 2007).  The iPS cells express various stem cell markers and are not  
programmed to display development of gene problems or tumors (Takahashi et al., 2007).  In 
terms of cellular morphology, mouse iPS cells were more clustered and less flattened than 
normal human ES cells.  Subsequent iPS studies showed that plasmids encoding three 
transcription factors, then only two transcription factors, could produce mouse iPS cells (Scott, 
2007).   
Human iPS cells were first derived, in 2007, by Dr. Shinya Yamanaka of Kyoto 
University in Japan (Takahashi et al., 2007).  Yamanaka and his team used retroviruses encoding 
the five transcription factors of Oct-3, Oct-4, Sox-2, c-Myc, and Kif4, to perform the 
dedifferentiation of skin fibroblast cells (Takahashi et al., 2007).  The human iPS cells had tight, 
flat, and sharp-edged cell colonies similar to human ES cells.  It was determined that the c-Myc 
caused some of the cells to become tumorous, so in a subsequent experiment c-Myc was omitted 
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from the transcription factor mixture (Takahashi et al., 2007).  In Feburary 2008, James 
Thomson and Junying Ju of the University of Wisconsin-Madison used a lentiviral system 
encoding transcription factors of Oct-4, Sox-2, Nanog, and a different gene of Lin28, with no c-
Myc, to create iPS cells (University of Wisconsin, 2007).   This research team genetically 
reprogrammed human dermal fibroblasts from a baby‟s foreskin to create iPS cells that do not 
derive from embryos (University of Wisconsin, 2007). 
As Ian Wilmut, the famous English embryologist at the University of Edinburgh who 
produced Dolly the world‟s first cloned mammal, said about iPS cells, “These new cells are 
expected to live a very long time, while retaining the ability to form into different tissues in the 
human body” (Bedford Research Foundation, 2008).  
More recently, in April 2009, stem cell researcher Sheng Ding and his team at the Scripps 
Research Institute in La Jolla, CA, found that iPS cells could be created without any genetic 
alteration by inducing the cells with poly-arginine anchors (Reprogramming Offers Hope of 
Safer Stem Cells, 2009).  Using mouse fetuses the researchers isolated connective tissue 
fibroblasts, and then incubated them in a bath of four polyarginine proteins for twelve hours, 
removed the proteins for thirty-six hours, and continued this cycle of events four times 
(Reprogramming Offers Hope of Safer Stem Cells, 2009).  After two weeks, iPS cell colonies 
were created and all colonies did not develop cancer (Reprogramming Offers Hope of Safer 
Stem Cells, 2009). 
 
Chapter-1 Summary 
Embryonic, adult, and induced pluripotent cells are the three main groups of stem cells in 
research.  Embryonic stem cells are derived from the inner cell mass of an early stage embryo 
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known as a blastocyst.  The embryos are usually obtained from in vitro fertilization (IVF) clinics 
from couples who decide to donate their embryos for research.  Adult stem cells are 
undifferientiated cells that come from different organs and tissues in the adult body, and have a 
role to repair and maintain the tissue or organ that they are found in.  Examples of these cells 
include hematopoetic and mesenchymal stem cells that are beneficial for treating numerous 
diseases.  Induced pluripotent stem cells (iPS) or induced embryonic stem cells (iES) are stem 
cells that have the ability to become any type of cell in the adult body, but which are usually 
derived from non-pluripotent cells through expression of certain de-differentiation genes without 
using an embryo.  Among all the types of stem cells, iPS cells seem to hold the most promise for 
advancements in stem cell research, and will hopefully show the same pluripotency as ES cells 
derived from a fertilized embryo.  Future research seems to be focusing more on the use adult 
and iPS cells, as opposed to using embryonic stem cells. 
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CHAPTER-2:  STEM CELL APPLICATIONS 
Baurzhan Negmetzhanov 
 
Introduction 
Since the discovery of stem cells, these master cells of the body have been of great 
interest in the medical community because of their ability to differentiate into other cell types 
and regenerate tissues in the body.  Scientific research on stem cells has the potential to 
revolutionize the practice of medicine, and improve the quality and length of life.  The hope is 
that stem cell therapy can be used to treat devastating diseases such as cancer, spinal cord 
injuries, and Parkinson‟s disease.  The purpose of this chapter is to describe some of the 
applications of stem cell research, delineating applications still in the animal stage of research 
versus those applications already in human clinical trials. 
Stem cells are regenerative cells that have the ability to specialize and develop into 
different tissues of the body.  Unspecialized cells can be transformed to become heart tissue, skin 
cells, and other tissues. As discussed in chapter-1, embryonic stem (ES) cells are obtained from 
an embryo, while adult stem cells (ASCs) are obtained from adult tissues.  ES cells are ethically 
controversial since they destroy an embryo when obtaining them, while ASCs do not destroy an 
embryo and are less controversial.  ASCs are present in organs such as bone marrow, pancreas, 
brain, and umbilical cord blood.  With ASCs, physicians have already treated autoimmune 
diseases such as lupus, multiple sclerosis, rheumatoid arthritis, Parkinson‟s disease, multiple 
sclerosis, and spinal cord injuries (Earll, 2005; Hughes, 2005).  However, adult stem cells are 
less potent than ES cells, and are incapable of developing into every type of adult tissue (Weiss, 
2005).  
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Stem Cell Treatment of Diabetes 
Diabetes is the seventh leading cause of death in the United States today, with nearly 
200,000 deaths reported each year.  According to the American Diabetes Association, nearly 16 
million people or 5.9 percent of the United States population have diabetes (Stem Cells and 
Diabetes, 2005).  Type-I diabetes is a disease that results from the destruction of the pancreatic 
cells (β-cells) that produce insulin. The glucose level in the blood increases when insulin is 
insufficient. The common treatment for those who suffer from type-I diabetes is direct injection 
of insulin.  Another treatment for these patients includes human islet cell transplantation to 
restore insulin secretion; however the transplants are often rejected as with most transplants. 
Also, this cell transplant technique is rare and only a small percentage of patients get a chance to 
receive one (Assady et al., 2001).  
Embryonic stem cells have the potential to differentiate into insulin producing cells while 
avoiding immune attack and graft rejection, so these cells hold promise for physicians, 
researchers, and patients for a cure.  Human ES cells have already been shown to be capable of 
differentiating into insulin-producing cells in vitro (Assady et al., 2001; Lumelsky et al., 2001; 
D‟Amour, 2006).  Armed with a ready supply of cultured ES cells grown from an ES cell line, 
these cells could in the future be applied to human patients.  Before transplantation, the ES cells 
could be engineered to avoid immune rejection by placing them in nonimmunogenic media, thus 
allowing patients to escape the negative effects of immunosuppressant drugs (Stem Cells and 
Diabetes, 2005).  
In addition to using ES cells, the possibility of using adult stem cells to treat type-I 
diabetes has also been explored on animal models.  In one study, researchers genetically induced 
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mice to become diabetic, and then bone marrow stem cells were injected into the blood stream of 
the diabetic mice. After two weeks, researchers observed that insulin production had increased 
and glucose levels had dropped to normal (Hess et al, 2003). Researchers have made a 
remarkable progress in applying this stem technique in animals; however expanding the 
approach to humans may be years away. 
 
Stem Cell Treatment of Damaged Heart Muscle 
Heart disease is the leading cause of death in the world and in the United States.  Heart 
disease and other heart ailments affect millions of people, and the number of cases is increasing 
with an ageing population. Although there are numerous drugs for treating heart disease, these 
drugs only alleviate the symptoms, or slow the progression of the disease.  But recent research on 
stem cells has shown that these cells could be used to treat patients who have suffered from a 
heart attack.  This stem cell approach has a great advantage over heart transplantation, since the 
number of heart attack patients far outweighs the number available organs. 
With respect to adult stem cell treatments of heart attacks, human heart attack patients 
have already been treated with adult cardiac stem cells (Britten et al., 2003; Siminiak et al., 
2004) or with adult bone marrow stem cells (Lunde et al., 2006; Schächinger et al., 2006).  
Injection of human bone marrow stem cells into damaged tissues of a patient‟s heart induced 
them to form new cardiomyocytes, vascular endothelial cells, and smooth muscle cells, thus 
partially repairing the damaged region of the heart.  Patients treated with bone marrow stem cells 
experienced a lower number of adverse effects such as cardiac arrhythmias, and showed signs of 
significant improvements in heart, lung, and global function, compared to those patients who 
received a placebo (Schächinger et al., 2006).  However, other studies showed no statistically 
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significant difference in patients receiving the stem cell treatment (Lunde et.al, 2006), so more 
research is needed.  With respect to embryonic stem cells, human ES cells have already been 
shown to be capable of differentiating into various cardiac lineages in vitro (Kehat et al., 2001). 
The human stem cell experiments were based on prior experiments with mice which 
showed that mouse ES cells are able to differentiate into contracting cardiomyocytes in vitro 
(Kehat et.al, 2001).  Additional experiments have been performed with mice in vivo.  Injection of 
hematopoetic stem cells (HSCs) in vivo provided an effective stem cell therapy for heart disease 
(Figure-1).  It was observed that HSCs were able to differentiate into cardiomyocytes and 
vascular endothelial cells in the damaged part of the heart (Orlic et. al, 2001). Using this animal 
model researchers also have discovered that after injection of bone marrow stem cells into the 
damaged heart, newly formed tissues occupied sixty-eight percent of the damaged region only 
nine days after treatment (Figure-1). Moreover, the mice treated with stem cells survived in 
larger numbers than the mice that did not receive any treatment (Can Stem Cells Repair a 
Damaged Heart, 2006).   
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Figure 1: Adult Stem Cell Therapy in Heart Diseased Mice. This 
illustration shows how adult stem cells are injected into the damaged part of a 
mouse heart, which induces repair of heart tissue and growth of new cells in 
the region (Can Stem Cells Repair a Damaged Heart, 2005). 
 
 
Hematopoietic Stem Cell Applications 
One of the first applications using stem cells of any kind was the treatment of leukemia 
patients with hematopoietic stem cells (HSCs).  HSCs have been used since 1959 in bone 
marrow transplants; world-wide about 40,000 transplants are performed annually (Horowitz, 
1999).  Leukemia results from an uncontrolled proliferation of immature white blood cells that 
are the part of immune system. The high level of immature white cells in the blood causes a 
cancerous blood stream and compromised immune system that can kill the individual.  In the 
leukemia treatment process, the patient undergoes chemotherapy which destroys cancerous 
HSCs and then his or her HSCs are replaced with a bone marrow transplant from a 
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histocompatible donor.  The bone marrow (containing HSCs) is taken from a donor (usually a 
close relative) and injected into the patients‟ blood stream, where the HSCs differentiate into all 
the cellular components of the blood.  The transplant procedure has saved thousands of lives to 
date, although finding a histocompatible donor remains difficult (Hematopoietic Stem Cells, 
2005).   
Another way that leukemia has been treated with HSCs involved removing bone marrow 
from the leukemia patient, irradiating the patient to destroy cancer cells, and then re-injecting the 
patient‟s own HSCs back in the bloodstream.  Because the patient gets back his own cells, the 
risk of graft rejection is significantly reduced, however there is a risk that cancer cells may still 
reside in the returned bone marrow and the patient can regain leukemia (Thomas, 2000).  As 
more immuno-rejection drugs were developed, bone marrow transplants became more common 
and were applied to other blood diseases that were previously incurable. 
The most famous treatment involving HSCs in the United States occurred in 1984. The 
patient suffered from a genetic disease known as SCID (Severe Combined Immunodeficiency). 
The disease is very rare, however usually fatal soon after birth. The patient with SCID cannot 
fight off any infection due to the absence of the primary immune system defense cells. David 
Vetter (also known as “bubble boy”), a young boy with SCID was living in a germ-free bubble 
for his entire life.  In an attempt at treatment, he was given HSCs in order to overcome SCID. 
The bone marrow from his sister was injected into “bubble boy” to see if it would specialize into 
the immune cells needed.  Although the experiment was a success, it was discovered that his 
sister had Epstein-Barr virus in her bone marrow.  David could not fight the virus because his 
immune system was not developed, and he eventually died (McVicker, 1997). The HSC gene 
therapy treatment has subsequently been applied to other SCID patients with success 
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(Cavazzana-Calvo et al., 2000).  Although HSCs have been successful in treating leukemia, 
HSCs have a great potential for treating other cancers, while continuing to avoid the ethical traps 
of working with embryonic stem cells.  
 
Stem Cell Applications for Spinal Cord Injuries  
Each year, over 11,000 Americans suffer from spinal cord injury. Spinal cord injuries 
usually are permanent since myelin cells lose their ability to regenerate. Myelin cells form an 
insulating layer around nerve fibers to facilitate signal transmission, and are important for 
transmitting signals from brain. However, according to animal studies, stem cells can repair 
damaged spinal cord tissue and restore function, which offers hope for treating spinal cord 
trauma patients. Although much more research is needed, recent rat studies have shown that stem 
cell therapy holds promise for repairing spinal cord injury (Stem Cell Treatment Succeeds In 
Spinal Cord-injured Rats, 2005). 
 One study performed at Reeve-Irvine Research Center at UC Irvine showed that a human 
ES stem cell treatment of rats can restore myelin cells and neurons within seven days after the 
initial injury.  The most remarkable result was that the rats regained a limited mobility of their 
legs that had been previously lost.  However, the same treatment did not work on the rats injured 
for more than ten months, so the treatment needs to be applied soon after the injury (Stem Cell 
Treatment Improves Mobility after Spinal Cord Injury, 2005).  
Another study showed that in cases where rodent brain stem cells restored myelin in the 
injured rat spine, the rats showed some recovery, and walked with more coordination.  Adult 
neural stem cells (NSCs) taken from the brains of adult mice were labeled with a fluorescent 
marker, enabling researchers to trace those cells after they were transplanted into rats whose 
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spines had been crushed.  NSCs transplanted into rats only two weeks after the initial injury 
survived.  More than one-third of the transplanted NSCs traveled along the spinal cord, fused 
with the damaged tissue, developed into the type of cells that were destroyed at the injured site, 
and produced myelin.  As was found in the previous experiment, "the maximal effect of 
transplanting these cells is early after injury," says New York University School of Medicine 
professor Moses Chao, PhD.  "The timing of NSC application therefore is critical to successful 
therapy in the injured spinal cord" (Society for Neuroscience, 2006). Both of these key studies 
show the potential of using NSC and ES cell-derived therapies for the treatment of spinal cord 
damage in rats, and show the treatment is most effective during early stages of the injury 
(Vasich, 2005).  
Thus based on animal research, both ES cells and adult stem cells have a great potential 
for spinal cord injury cure. The biggest obstacle that researchers will face is applying methods on 
humans which will require a more in depth knowledge of stem cells and the spinal cord than the 
animal models can teach us. 
 
Stem Cell Treatment of Parkinson’s disease 
Parkinson‟s disease (PD) is a neurological disease that affects a certain part of the brain 
which contains neurons that secrete a chemical neurotransmitter known as dopamine. The lack of 
dopamine causes shaking throughout the body and difficulty when walking or maintaining 
normal posture. This devastating neurodegenerative disease most commonly affects people over 
the age of 50 (National Institute for Neurological Disorders and Stroke, 2009).  Although some 
drugs are available to improve symptoms (such as Sinemet) the effects are only temporary, thus 
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researches have been trying to use different types of stem cells in animal models to find an 
effective treatment for this disorder.  
Using a rodent model of Parkinson‟s disease with symptoms that are similar to human 
patients, researchers transplanted mouse ES cells into the damaged part of brain of a PD rat (Kim 
et. al, 2002).  The injected ES cells were able to differentiate into neurons that produce 
dopamine, and the rats regained some lost functions.  
Another similar approach was used by Bjorklund and his colleagues who used mouse ES 
cells to differentiate them in vitro into neuronal stem cells, and then transplanted them into a PD 
rat‟s brain (Bjorklund et. al, 2002).  This study showed that the injected stem cells became 
dopamine producing cells, and improved the diseased rat‟s motor function.  A possible obstacle 
that researchers may encounter with this approach is immune system rejection of the ES cells.  In 
the animal model treatments discussed here, the rats were given powerful anti rejection drugs to 
help prevent loss of the ES cells. 
Some success has been observed treating human PD patients.  In a recent human clinical 
trial, fetal brain tissue was transplanted into the brains of Parkinson's disease patients.  The 
results showed major and long-lasting improvements in some of the patients (National Institute 
for Neurological Disorders and Stroke, 2009).  Other studies with fetal tissue explants have also 
shown some success (Madrazo et al., 1988; Lindvall et al., 1989; Freed et al., 2001, Mendez et 
al., 2002; Vogel, 2005).  However, experiments using fetal tissue have even more ethical issues 
than working with ES cells, since fetuses are more mature than the 5-day old blastocysts used to 
derive ES cells.  Human fetuses are usually obtained from abortion procedures instead of IVF 
clinics that provide blastocyst embryos.  But the experiment provides a proof of principal that 
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embryonic tissue (containing stem cells) can be used to repair the area of the brain damaged in 
Parkinson‟s patients, so a stem cell approach may eventually work in the future. 
 
Neural Stem Cells and Alzheimer’s disease 
Another neurological disease that has been important in the stem cell debate is 
Alzheimer‟s disease (AD).  AD is a neurodegenerative disease that usually affects the elderly, 
and is one of the leading causes of late life dementia. The challenge for the stem cell therapy 
with Alzheimer‟s disease is that unlike Parkinson‟s, AD neurodegeneration affects different 
regions in the brain, while Parkinson‟s only affects the substantia nigra.  Research showed that 
treating bone marrow cells with bromodeoxyuridine (a compound that incorporates into 
replicating DNA) induced the bone marrow cells to develop into brain cells after they were 
transplanted into adult rat brains (Binette, 2005).  A significant advantage of this technique is 
that there is no danger of immune system rejection because the cells come from the same patient. 
The positive neural functionality of the transplanted cells observed in this study provides hope 
for treating Alzheimer‟s disease in the future (Binette, 2005).  
 
Human Clinical Application of Stem Cells 
 
In those cases where our information on a particular stem cell application comes only 
from animal studies, scientists debate when to move into human clinical trials.  Most physicians 
agree that many years of animal study are required before moving into human applications, but 
as discussed above, some diseases are already being tested in humans with stem cells.  As 
discussed above, scientists are still in animal studies using stem cells to treat diabetes and spinal 
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cord injuries.  But scientists have used hematopoietic stem cell transplants since 1959 to treat 
leukemia and a variety of other disorders, and have already begun to treat heart attack patients  
with adult cardiac stem cells (Britten et al., 2003; Siminiak et al., 2004) or with adult bone 
marrow stem cells (Lunde et al., 2006; Schächinger et al., 2006).  And fetal tissue explants 
(containing stem cells) have already been used to treat Parkinson‟s patients (Madrazo et al., 
1988; Lindvall et al., 1989; Freed et al., 2001, Mendez et al., 2002; Vogel, 2005; Zandonella, 
2005). 
The use of controversial but powerful ES cells in humans has not yet been performed, but 
Geron Company suggests that ES cell therapy can be safe and effective for a select group of 
patients suffering from spinal cord injury. Many researchers caution that Geron‟s plans can make 
an already controversial field even worse, as ES cells from mice and humans have proven 
difficult to control, differentiating into the wrong kind of cell, or migrating away from the 
injection site.  However, on January 23, 2009, the US food and drug administration (FDA) 
announced the approval of the first clinical trial using human embryonic stem cells to Geron to 
treat spinal cord injuries. Supporters of stem cell research praised the FDA approval, saying that 
any trial is important for moving forward (Wadman, 2009). Still, many researchers worry that 
Geron is moving too fast, warning about the possible side effects and immuno rejection. 
However, patients who suffer from various disorders ask researchers to continue their studies. 
The approval of ES cell clinical trials is very significant for the further investigation of stem cell 
applications.  
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Chapter-2 Conclusions 
Because stem cells (depending on their type) can differentiate into a variety of tissues, the 
hope is these cells might be used to treat previously uncurable diseases, such as Alzheimer‟s, 
multiple sclerosis, diabetes, Parkinson‟s, heart attacks, spinal cord injuries, etc.  More research is 
needed, but significant progress has already been achieved.  Human adult stem cells have already 
been used to treat leukemia patients since 1959, and have more recently been used to treat 
patients with heart attacks.  Fetal cells have been used to treat patients with Parkinson‟s disease.  
Humans have not yet been treated with embryonic stem cells, although the FDA in January 2009 
provided approval for Geron to treat spinal cord patients.  The stem cell treatments will remain 
controversial, and the graft may sometimes become immunorejected, but these treatments remain 
the only hope for some diseases previously thought to be incurable. 
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Chapter 3:  Stem Cell Ethics 
 
Shaaz Shuttari 
 
The question of the use of the embryos in research has been a hot topic of debate since 
the late 1960‟s, when in vitro fertilization (IVF) clinics first appeared.  With respect to stem 
cells, as discussed previously ES cells are usually obtained from embryos.  This process destroys 
the embryo, so ES cell usage has ethical considerations.  The ethical considerations against using 
ES cells has led to advancements in less controversial cells such as adult stem cells (ASCs) or 
induced pluripotent stem (iPS) cells.  The purpose of this chapter is to go beyond the technology 
of stem cell usage to discuss whether we “should” work with such cells. 
The stem cell debate invariably focuses on when life begins.  According to a poll by ABC 
News and the Washington Post in 2007, 61% of Americans support embryonic stem cell research 
while 31% oppose this type of research (ABC News, 2007).   For many supporters of this 
research, such as researchers and family members with cancer, they believe that life begins for 
an embryo when it is united in reproduction with sperm in a woman‟s womb (O‟Mathuna, 1999).   
Outside the woman‟s womb, the embryo is just a lifeless ball of cells, and it should be used to 
benefit mankind and not be wasted (Dorff, 2001).  On the other hand religious fundamentalists, 
such as Southern Baptists, believe that all embryos have basic human rights of life, liberty, and 
the pursuit of happiness, regardless of how they were created or what stage of development they 
are in (“U.S. Bishops Protest”, 2006).  No matter what environment the embryo is put under, it is 
still a potential human being and should not be destroyed for experimentation (Catholic Online, 
2008).  Different world religions hold different views on when life begins.  Religious groups, 
such as Jews and Muslims, believe that embryos are considered humans only after about day 40 
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when ensoulment occurs.  Prior to this, the embryo is only a “watery substance”, so blastosysts at 
day-5 can be researched according to these religions.  Groups such as Roman Catholics believe 
that all fertilized embryos, no matter what environment they are placed in or their age, are human 
beings and should not be experimented with.  These opposing religious views constitute the fire 
of one of the most important debates in all of biomedical research. 
 
When Does Life Begin? 
Researchers, philosophers, and politicians have debated when an embryo becomes human 
for at least 2000 years (Dorff, 2001).  Philosophers, such as Aristotle, believed that life comes in 
three stages, defined as the vegetative, animate, and intellectual stages (Dorff, 2001).  In 
referring to human development, the embryo starts growing in a mother‟s womb in a vegetative 
stage.  When muscles begin to form and limbs start to move, this new human being is in an 
animate stage.  Finally the newly created human being will develop its intellect during the 
intellectual stage (Dorff, 2001).  Most people agree that the first two stages occur in the mother‟s 
womb and the last stage appears after birth.  Using Aristotle‟s thoughts, many believe that the 
embryo does not become human until after it is born.  
Modern day researchers such as Dr. John Caplan, a science ethicist, seem to have 
followed many of Aristotle‟s beliefs.  Caplan believes that cloned human embryos are not yet 
human.  Even the CEO of Advanced Cell Technology Inc. in Worcester, MA, Dr. Michael West, 
has agreed with this assessment to allow therapeutic research.  However reactions to the 
completion of the 2003 Human Genome Project have interestingly disagreed with Aristotle‟s 
teachings (Bellomo, 2006).  For the first time we now have access to information contained in 
our genome which can eventually tell what type of person someone is, what shapes someone‟s 
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body, and perhaps even someone‟s level of intellect (Bellomo, 2006).  Human genomes are 
present in human embryos and these scientists were quoted as saying the embryos are human, 
although this is different than saying IVF embryos should have the same status as an embryo in a 
womb (Bellomo, 2006).  To counter these arguments, Caplan and West claimed that they were 
referring to cloned embryos, thinking that they are “less than human” (Bellomo, 2006).  Other 
scientists disbelieve their statements of cloned embryos being different from their true genetic 
genomes.  Dr. Ian Wilmut was the British scientist who led the team that cloned Dolly the sheep 
and went to great lengths to prove to the world that Dolly was like any other sheep within her 
breed (Bellomo, 2006).  Wilmut and his team showed that Dolly being cloned didn‟t change the 
fact that she is a sheep, and if an embryo has any type of sheep genome then it is always a sheep 
(Bellomo, 2006).  Using Wilmut‟s study, if a human embryo has any type of human genome then 
that embryo has to be human (Bellomo, 2006).  The idea of genomics claims that the identity of a 
species is shown in its genes and can be used to show that the embryo is human from its date of 
birth. 
As this ethical debate continues, many believe that it is false to redefine ideas related to 
being a human as listed in the Belmont Report (Bellomo, 2006).  It is clear that an embryo 
containing a human genome is human, but in view of IVF technology, the debate has expanded 
to determine what status an embryo has outside the womb when it can not become fully human. 
 
Positions Against ES Cell Research 
Those who don‟t believe in ES cell research, such as Evangelicalist priests and former 
President George W. Bush, believe that the ball of cells that make up the early embryo is a 
human being entitled to certain rights (Catholic Online, 2008).  As stated in the Declaration of 
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Independence, all human beings have the right to life, liberty, and the pursuit of happiness.  All 
human beings are equal because all of us display these three fundamental rights, especially the 
right to life (Catholic Online, 2008).  Without securing the right to life, the two other rights in the 
Declaration of Independence can‟t be attained (Catholic Online, 2008).  There is a strong belief 
that any living being should have the right to life, and should not have to be dismantled for any 
research purposes (Teaching About Religion, 2006).  Embryonic research appears to attack these 
principals as not giving any humanistic rights to human beings (Dorff, 2001).  Any person has 
the right to life.  Since this camp argues that embryos are considered humans, these opposers of 
ES cell research believe that embryos should have full protection under the law (Dorff, 2001). 
 Before fertilization the egg and sperm are two separate living cells that are genetically 
part of all human beings, and when these two gametes unite they form a human being (Teaching 
About Religion, 2006).  A human embryo is not a cell, but an organism in the early stage of 
human development (O‟Mathuna, 1999).  An embryo needs a well-maintained environment and 
sufficient nutrition, and has the capability to grow and develop (Catholic Online, 2008).  Identity 
has importance in any type of living being, for example when someone is sick, that person 
doesn‟t say, “my body is sick” but “I‟m sick.”  Each embryo is genetically different and should 
be recognized with the identities the living humans keep (O‟Mathuna, 1999).  
 The terms adult, teenager, and embryo are all manifestations of the same organism that 
happens to grow with age and go through different life stages.  Developmental biology shows 
that our bodies originate at fertilization, and therefore a human embryo is a person because it is 
the same human being and organism as it is in an adult (Dorff, 2001).  Supporters against ES cell 
research claim that each person and embryo is valuable, thus other more ethically permissible 
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methods in regenerative medicine, such as using adult stem cells or induced pluripotent stem 
cells, should be used to respect the dignity of every human life (Dorff, 2001). 
 
Positions for ES Cell Research   
 Although numerous people are against ES cell research, there is a much higher number of 
supporters (Dorff, 2001).  For example, recently President Barack Obama signed a bill that lifted 
the previous restrictions on federal funding for ES cell research.  Through painstaking trial and 
error research, supporters and scientists hope to utilize stem cells to help people with severe 
illnesses and diseases live longer. 
 Many of these supporters of ES cell research agree with non-supporters that eggs and 
sperm are living cells before conception (Bellomo, 2006).  Embryos should be considered as 
human beings of the species Homo sapiens, but similarly something as small as a neuron or 
blood cell is human too (Bellomo, 2006).  The main difference is that this ES cell support group 
believes IVF embryos originally created for reproductive purposes that are discarded, although 
they are alive, only have the ability to produce a life, and have less moral status than an embryo 
inside the womb.  Consider a couple producing IVF embryos to have a family.  Because the 
implantation process into the uterus is inefficient, extra embryos are usually created.  The 
decision as to whether to implant the embryos or to donate them for research is fully the couple‟s 
(Bellomo, 2006).  The woman then declines for a uterine transfer into her or anyone else, and she 
and her partner decide to donate the embryo to medicine, clearly stating in their donation no type 
of uterine transfer (Bellomo, 2006).  Outside the womb an embryo can not develop beyond ten 
days, and if scientists used this embryo for research a full fetus will not develop (Bellomo, 
2006).   Gestation can‟t occur for the embryo and it can‟t experience frustration or pain, as it has 
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no nervous system.  If the donated embryo is not used for research, it is usually destroyed 
(Bellomo, 2006). 
 The theory of mutual aid instructs us to come to the help of others in peril, when it can be 
done effectively (O‟Mathuna, 1999).   The use of donated embryos could be used to help 
suffering humans with no cost in real lives but with medical gains (O‟Mathuna, 1999).   In this 
manner, mutual aid should be applied to donated IVF embryos, with its reduced role as potential 
human life (O‟Mathuna, 1999). 
 
Catholic Stance on ES Cells 
    Interestingly, zygotic personhood has not been in agreement with most of the Catholic 
Church‟s view for the last two thousand years (Bellomo, 2006).  The early Church followed 
Aristotle‟s hylomorphic view that not until day forty does an embryo reaches a human form with 
a body and soul (Catholic Online, 2008).  As the philosopher Thomas Aquinas said about the 
status of the embryo, “prior to ensoulment, conception isn‟t completed” (Catholic Online, 2008).  
Thus the consequences of abortion were dependent upon the embryo‟s time of gestation.  The 
views changed in 1869, when Pope Pious IX said that people who believe in abortion shouldn‟t 
be regarded as followers of God (Bellomo, 2006).  Because Pope Pious IX did not pay attention 
to the time of gestation, his ideas came to agree with zygotic personhood (Robinson, 2006).  
 In 1987 a new view by the Catholic Church, Donum Vitae, suggested personhood as a 
philosophical question that was open to different interpretations (Bellomo, 2006).  There were no 
signs of any type of interpretation from scriptures, and ancients did not understand embryos in 
petri dishes.  In 1974, the Declarato de Aborto Procurato, suggested that the Roman Catholic 
Church identifies a person with a new genome (Bellomo, 2006).  When fertilization creates a 
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new genome, it also creates a new person (Bellomo, 2006).  The idea that a genome serves as a 
person, describes a radical view of genetic reductionism that causes mixed views on the concept 
of fertilization (Bellomo, 2006).  Since zygotic personhood occurs before any type of soul, 
personality, or conscientiousness, then zygotic personhood can interestingly be viewed as a 
stance against abortion (Robinson, 2006).   
A large majority of practicing Catholics has been opposed to ES cell research because it 
involves the destruction of human life by dismantling human embryos.  Pope John Paul II said, 
“embryonic research is related to abortion, euthanasia, and other attacks on innocent life” (CNN 
2001).  The basis of their opposition was released in August 25, 2008 by the Pontifical Academy 
for Life in the “Declaration on the Production and Scientific and Therapeutic Use of Human 
Embryonic Stem Cells” (Catholic Online, 2008).  This declaration listed three major reasons why 
the Catholic Church opposes ES cell research.  The first reason involves the preparation of ES 
cells and how this process involves the destruction of the embryo, which the Church thinks is an 
immoral act (“U.S. Bishops Protest”, 2006).  The second reason involves the belief that scientists 
use unnatural techniques to produce embryos to harvest stem cells, which should be considered 
immoral (“U.S. Bishops Protest”, 2006). The third reason claims that the Church opposes the use 
of ES cell lines that already exist because these stem cell lines began with the destruction of 
innocent human life (“U.S. Bishops Protest”, 2006).  Overall, the Church does not care if 
scientific advances are made through ES cell research, as the end does not justify the means.  
The Church teaches that we can never do anything evil even if benefits come out of it.  This 
harsh stance against ES cell research places strong incentives to work with adult stem cells or 
iPS cells, which do not destroy embryos.  The Pope has been cited several times as being in favor 
of research with adult stem cells (Catholic Online, 2008). 
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Jewish Stance on Stem Cells 
   Unlike most Catholic groups, Jews are much firmer supporters of the potential benefits 
that ES cells have.  Jewish tradition believes that our bodies belong to God, and thus God has the 
right to inflict conditions to our bodies (Eisenburg, 2006).  A requirement that Jews seek is to 
preserve human life, and it is a duty to create cures for diseases and develop methods that can 
help out with extending human life.  Physicians, scientists, and researchers all help towards 
preserving human life and developing therapies to help others, which all belong to God 
(Eisenburg, 2006).   Jews clearly state that humans aren‟t God; so all humans must take 
precautions to ensure our actions don‟t harm the world or ourselves (Eisenburg, 2006).  Jewish 
law claims that the embryo doesn‟t become human until forty days after conception, and also 
explains that the fetus doesn‟t become a person until its head emerges from the womb 
(Eisenburg, 2006).  Based on this timing, the Jewish stance allows research on embryos that are 
only five days old, from which ES cells are obtained. 
            According to the Talmud, during the first forty days of gestation, a fetus is “as if it were 
simply water,” and forty-first day until birth is “like the thigh of its mother” (University of 
Judaism, 2001).  No one can amputate their own thigh because it would injure the body that 
belongs to God, however if the thigh is infected then it should be amputated to save someone‟s 
life.  All embryos, in vitro or in vivo, until forty days old have less legal status in Jewish law than 
older fetuses, because they are classified by the Talmud “as if simply water” (University of 
Judaism, 2001).  All Jews believe that health care is a community responsibility and it‟s required 
to look after those in poor health until they fully recover.  With the potential that embryonic 
research has for curing diseases and aliments, Jews strongly believe that it is a duty placed upon 
God to proceed with this research (University of Judaism, 2001). 
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Muslim Stance on Stem Cells 
 Islam has similar views to Judaism on ES cell research.  Muslims claim that the fetus is 
considered human life only later in biological development than the time ES cells would be 
isolated (Siddiqi, 2002).  Proof of this statement is found in the Quranic verse “thereafter we 
produced him as another creature,” referring to when a fully developed fetus is taken out of the 
mother‟s womb (Siddiqi, 2002).  Islamic scholars claim that ensoulment of the fetus does not 
occur until the end of the fourth month of pregnancy or 120 days (Siddiqi, 2002).  Islamic 
tradition describes the ensoulment of the fetus as, “each of you possesses his own formation 
within his mother‟s womb, first as a drop of matter for forty days, then blood clot for forty days, 
then as a blob for forty days, and then the angel is sent to breathe life into him” (Siddiqi, 2002).  
Under Shari‟ah law there is a difference between potential and actual life, with actual life having 
more importance and significance than potential life (Kutty, 2007).  Thus an embryo at five days 
is not considered fully human, and its use in ES cell research does not conflict with Islamic law 
(Kutty, 2007).   Current research on ES cells in the early stages of an embryo‟s life is perceived 
as an act of faith towards God as the ultimate creator, and a great humanistic act towards helping 
others in poor health, a key Islamic principle to help others that are in need.  
 
Hindu and Buddhist Stances on Stem Cells 
 There are numerous conflicting notions for ES cell research made by Hinduism and 
Buddhism.  These Eastern religions believe in reincarnation and the idea that life starts before 
conception (Hinduism and Modern Science, 2006).   Both religions view human incarnation as 
the opportunity to attain enlightenment, the best state that a soul can attain.  For example as 
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described in the Upanishads, “the soul is present in any form even in human sperm” (Hinduism 
and Modern Science, 2006).   Hindus view life as sacred in all forms and believe that conception 
is the beginning of the soul‟s rebirth from a previous life (Tyagananda, 2002).  Hindu tradition 
shows that personhood begins between around three to five months of gestation, while 
incarnation occurs as late as the seventh month (Tyagananda, 2002).  A central tenet in Hindu 
religion stresses to avoid harming living things, and its main tenet preaches to practice 
compassion towards one another (Tyagananda 2002).  Thus, based on this ensoulment stance, 
these religions would be against ES cell research since the five-day embryo is already ensouled 
and should not be harmed.   
 Alternatively the 2,700-year-old epic text of India, The Mahabharata, claims that it is 
acceptable to sacrifice a son for the family, or the family for the village, which leads to some 
agreement with ES cell research as an embryo could be sacrificed to save lives (Tyagananda, 
2002).    
    Many Buddhists think that the soul has some effect on where to reincarnate, and the 
soul may not want to enter an embryo in a Petri dish with no opportunity to ever grow 
(Mahathera, 1994).  The story of the Kaurava brothers offers an early example of human cloning 
through stem cells extracted from human embryos. The story described how the mother of the 
Kaurava brothers had obtained a mound of flesh, and two years after pregnancy a sage divided 
the flesh into a hundred parts, treated with butter and herbs, and kept this mixture in a pot 
(Tyagananda, 2002).   After two years, the Kaurava brothers finally emerged as human beings 
(Tyagananda, 2002).  The two main tenets in Buddhism involve the prohibition against harming 
or destroying others, and pursuing knowledge and compassion to benefit mankind (Mahathera, 
1994).  The second tenet agrees with the principles displayed by embryonic research, but the first 
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tenet would never allow any type of embryonic research.  Both Hindus and Buddhists agree that 
personhood begins at conception and that an individual‟s self and soul is eternal (Mahathera, 
1994).  Adult stem cell research is widely accepted amongst Hindus and Buddhists, though 
there‟s mixed views on ES cell research displayed by their tenets.  Currently a majority of 
practicing Hindus and Buddhists would agree with ES cell research if it aids the health and well 
being of society.  
 
Chapter-3 Conclusion 
 Embryonic stem cells are the only type of stem cell under strong ethical debate.  No 
major world religion or country argues against the use of adult stem cells.  Supporters of ES cell 
research point to the many potential benefits to society in aiding people with various diseases, 
especially utilizing excess IVF embryos that are already slated for destruction.  Those opposed to 
ES cell research argue that the embryo is potential human life, even outside the human body, 
which has the right to life.  Various religions have different views on ES cell research.  Many 
forms of Catholicism are strongly opposed to using embryos for any research claiming life 
begins at conception, and it is a cardinal sin to destroy any type of life.  Judaism and Islam are 
supporters of ES cell research due to their stances that human life for an embryo does not begin 
until at least forty days after conception and after the five day period when ES cells would be 
isolated.  Hinduism and Buddhism have mixed views on ES cell research, with opponents 
explaining that souls are eternal, sperm and egg prior to fertilization have souls, and that life is 
sacred in any form.  Proponents argue Hindus and Buddhists should pursue knowledge and 
compassion to help those in need.  In August 2007, the Pew Research Center for the People and 
Press asked the question whether ES cell research should continue, and received results that 
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claim 51% of the public, regardless of religion, are for ES cell research, 35% are against, and 
14% were undecided (ABC News, 2007).  The ultimate question of whether embryonic stem cell 
research should continue or not, lies in the hands of politicians, religious leaders, and the general 
population.  
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CHAPTER-4: STEM CELL LAWS 
Baurzhan Negmetzhanov 
 
Introduction 
Medicine has witnessed an amazing potential transformation in the last few decades from 
stem cell research. As discussed in Chapter-2, some types of stem cells (especially hematopoietic 
stem cells) have already been used to save thousands of lives in medical applications.  Other 
types of adult stem cells are already being tested for treating heart attack patients (Adult Stem 
Cells, 2006).  And as of January 2009, the FDA finally approved pharmaceutical company Geron 
to use embryonic stem (ES) cells to treat spinal cord injuries.  But as is typical of any complex 
technology, laws have been enacted to regulate procedures that can be performed with stem cells.  
The purpose of this chapter is to discuss some of the past and current US federal, state, and 
international laws pertaining to stem cell use.  This chapter should provide an appreciation of the 
importance of legislation and the great consequences it has on stem cell research to dictate its 
progress. 
As was stated in earlier chapters, adult stem cell (ASC) research is far less controversial 
than ES cell research because the former does not destroy embryos.  All five major world 
religions favor working with adult stem cells to try to save lives (Christian Today, 2004).  
Accordingly few legal hindrances exist for this type of research, other than the usual patient 
consents, etc.  However, for ES cells, several major world religions do not support their use, and 
laws reflect a tight control over this type of research.  Questions arise whether people are willing 
to let stem cells research progress at the expense of religious and ethical beliefs (Christian 
Today, 2004).  Many people don‟t see this conflict so they support ES research, but those who 
 53 
hold ES research is wrong are burdened with a tough choice (Weiss, 2005).  Laws and 
regulations in societies are an expression of these different religious and scientific views.   As 
discussed below, the laws can vary considerably with a change of the variables, including a 
change in the elected congress, president, and people‟s views and education.  In the US, the past 
decade witnessed a repression of ES cell research, while the present sees a strong support of this 
research.  The future remains unknown. 
 
Stem Cell Legislation of the Past Decade 
I) The Federal Level 
Since the development of human in vitro fertilization (IVF) techniques in the late 1960‟s, 
ethical and legal issues surrounding the use of excess unused human embryos have been debated.  
In late 1970, the US Ethics Advisory Board decided that research using ES cells is ethically 
acceptable, so long as the research did not use embryos beyond fourteen days of development, 
but the research will not be funded by the federal government (Monitoring Stem Cell Research, 
2004).  In 1993, during President Clinton‟s presidency, the US Congress enacted the NIH 
Revitalization Act, which enabled NIH to fund human embryo research using excess IVF 
embryos.  The NIH also created a Human Embryo Research Panel (HERP) to consider stem cell 
research issues and to propose guidelines for potential research funding.  The panel 
recommended the funding of some areas of embryo research within the limits of ethical issues, 
even allowing eggs to be donated only for research purposes.  President Clinton accepted 
HERP‟s recommendations for allowing some types of embryo research, but rejected their 
suggestion of allowing egg donations solely for research purposes.  However, Congress did not 
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approve of any of HERP‟s recommendations, and banned the use of federal funds for any 
embryo research (Monitoring Stem Cell Research, 2004). 
In the past decade under President Bush and congress, ES cell research was repressed in 
the US (Dunn, 2005).  President Bush, who governed from 2000 to 2008, comes from a 
conservative Christian background, stating “I'm a strong supporter of adult stem cell research, of 
course. But I made it very clear to Congress that the use of federal money, taxpayers' money, to 
promote science which destroys life in order to save life is -- I'm against that” (Baker, 2005).   In 
2001, the senate was equally divided on the ES cell topic, but the House of Representatives held 
a republican majority (mostly conservatives). This information is important because there is a 
great divide between the supporters of ES research (mostly democrats) and those who do not 
support ES cell research (mostly republicans).  Statistics show that 76% of democrats support ES 
stem cell research, while only 44% of republicans support it (Langer, 2005).  These guidelines 
mostly apply to the US demographic since religions such Islam and Judaism do not oppose ES 
cell research (discussed in Chapter-3).   
The election of George W. Bush as President with a republican majority in the House of 
Representatives gave conservatives the upper hand.  This conservative view was manifested into 
action in August of 2001.  President Bush announced that as of that date, no federal money could 
be used to derive new ES cell lines, and researchers receiving such funds are restricted to using 
only ES cell lines derived before August 2001 (White House Press Release, 2001).  This 
effectively reduced the number of ES cell lines to only about 60.  This put a huge obstacle in 
front of ES cell research because the expensive cost of this type of research requires the help of 
the tax payers.  Also, the number of ES cell lines is not enough to progress in the field (Agnew, 
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2003).  And worse, the number of ES cell lines was originally thought to be around 60, but this 
was subsequently reduced to only 9 viable, non-mutated, unique lines (Abbott et al, 2006).  
 The rationale behind Bush„s decision is a moral and ethical one.  He considered ES cell 
research as committing “murder” since it destroys the embryo that can be considered a human 
life (Monitoring Stem Cell Research, 2004).  Research was allowed on the previously derived 
cell lines because those embryos were already destroyed.  In 2005, Bush vetoed a bill that would 
have lifted funding restrictions on human ES ell research.  Although the House and Senate had 
passed the bill, it was not by a margin large enough to override the President‟s veto.  The House 
had voted 235 to 193 to pass the bill.  The Democrats voted more heavily than the Republicans 
in favor of the bill (Babington, 2006). 
 
II) The State Level   
Seeing the prohibition of federal funding of this important ES cell technology, some 
states took it upon themselves to fund this research through state bonds (Holden, 2006).  
In 2004, New Jersey became the first state to support stem cell research funding $10 million to 
universities and commercial labs (Wadman, 2008). The move initiated by New Jersey is 
significant because it emphasizes the discontent that states had towards President Bush‟s 
regulations on stem cell research. California was the first state to officially oppose President 
Bush‟s restrictive policies on stem cell research. In 2002, the legislators of this state drafted a bill 
that would fund further research of HSCs using state money. California passed proposition 71, 
which enabled creation of California Institute for Regenerative Medicine and which provided 3 
billion dollars over 10 years to advance stem cell research (Hayden, 2008).    
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Massachusetts, which is known for being advanced in science and medicine, also 
responded to President Bush‟s ES cell research restriction policy. Because many leading medical 
institutions are located in Massachusetts, it was essential for its legislators to encourage stem cell 
research.  In 2005, Massachusetts Senate President Robert Travaglini created a bill that would 
formally support the research. The bill encouraged research involving adult stem cells, and also 
allowed embryos to be created by somatic cell nuclear transfer (therapeutic cloning).  The law 
also explicitly banned human reproductive cloning, and established penalties for those who 
abuse it (Finer, 2005).  Then Governor Mitt Romney vetoed the bill because he believed that the 
bill did not create safeguards against human cloning or the creation of embryos solely for 
research purposes (Holden, 2005).  However on May 30, 2005, the Massachusetts state 
legislature approved the bill in the senate 35 to 2, thus overriding Romney‟s veto (Finer, 2005).   
In 2007, then new Massachusetts Governor Deval Patrick promised 1 billion dollars to support 
stem cell research (Estes, 2007).  Governor Patrick‟s plan was very important for the scientific 
community, especially after Governor Romney‟s previous opposition towards ES cell research.  
State legislators were supportive of Patrick‟s plan, and it was approved in June of 2008 (Vestal, 
2009).   
Other states such as New York, Connecticut, Illinois, and Maryland also took similar 
actions (Stem Cell Legislation in the U.S. by State, 2005).  As of 2009, seven states have funded, 
five states have restricted, and three states have legalized ES cell research (Figure-2).  Although 
the list of the states supporting ES cell research is growing, these states remain in the minority. 
Most states have no legislations addressing ES cell research, but fortunately states such as 
Massachusetts and California support this research, and have many key research facilities and 
top researchers. Also, the state sponsorship of ES cell research gave birth to a healthy 
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competition among states which has pushed other states to join the competition. Although state 
funding is not a substitute for federal money, state funding will make a difference in the progress 
of the stem cell research.  
 
 
Figure 2: Individual State Embryonic Stem Cell Research 
Policies.  The map shows various U.S. states that approve and fund 
ES stem cell research.  As of 2009, seven states fund this type of 
research, five have restricted policies, and three states have legalized 
but not yet funded ES cell research (Vestal, 2009). 
 
III) The International Level 
On the international arena, ES cell research has also attracted both supporters and 
opponents.  The European Union which is comprised of 27 different countries has also been split 
on whether human ES cell research should be funded.  Countries such as Germany and Italy 
oppose the advance of ES cell research (Kim, 2002).  Those countries have exerted an effort to 
convince the EU to put restrictions on this technology (Deutsche Welle, 2006). However in July 
of 2006, the legislative body of the EU passed legislation allowing the funding of hES cell 
 58 
research. 65 billion U.S. dollars will be provided for hES cell research for those countries that 
made the research legal (Silva, 2006).  
Countries such as Australia, Sweden, UK, and South Korea support ES cell research.  In 
the UK, the government created an organization called the Human Fertilization and Embryology 
Authority to investigate and direct ES cell research on both scientific and ethical grounds 
(Davies, 2003).  South Korea is very active in this field, and is competing with the US in this 
area.  South Koreans have derived almost as many ES lines as the US (Kaplan, 2005). The 
Australian government enthusiastically supports ES cell research, creating the Australian Stem 
Cell Center (Stem Cell Research in Australia, 2003). Sweden is at the front line of this research. 
The ease of its regulations helped create more than 30 research groups, and nine Swedish 
institutions actively work on ES cell research (Sweden's Stem Cell Success, 2002).  
As other countries advanced, fear increased that the US would lag behind in this 
important technology. The United States has the greatest potential in this field because its 
institutions are fertile ground for this work, but regulations and laws worked against it in the last 
decade.  In 2009, with a change of president and congress, stem cell research funding did an 
about face in the US. 
 
Current Stem Cell Legislations 
In January 2009, the inauguration of new President Obama, a democrat, opened a new 
page in stem cell research. Within 3 months, President Obama passed an executive order 
allowing ES cell research to receive federal funding.  Obama said on 9 March, the same day he 
signed the order, “We will vigorously support scientists who pursue this research, and we will 
aim for America to lead the world in the discoveries it one day may yield” (Holden, 2009).  This 
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event was celebrated by supporters of ES cell research.  This order allows the NIH to provide 
researchers with grants to work on new ES cell lines.   
The new legislation comes with some restrictions.  For example, the embryos used to 
derive new ES cell lines must come from IVF clinics (i.e. are originally created for reproductive 
purposes) and must be accompanied by donor consent.  And no money can be used to pay 
volunteers to provide eggs solely for research purposes.  The legislation also empowers NIH 
with the authority to oversee the derivation of new ES cell lines to ensure compliance with the 
new guidelines.  But even with these restrictions, the new legislation provides federal funding for 
ES cell research, and according to some, the US is finally back and ready to fully delve into this 
important field because the world needs it. "This type of science is international, and the whole 
world has suffered from the previous short-sighted and rather bizarre US policy," remarks Robin 
Lovell-Badge of the National Institute for Medical Research in London (Holden, 2009). 
 
The Future  
The future is unpredictable for ES cell research in the US.  Funding and laws will be the 
determining factor for its success or failure.  In the future, if a president who shares a common 
ground with Bush is elected, we will see a repression of ES cell research. Congress is important 
because at least a 2/3 support for stem cell research is necessary to able to override any 
president‟s veto if necessary.  Also, since congress enacts the legislations, President Obama‟s 
support of ES cell research could be disturbed by congress if the current democratic majority 
were to change in new elections to a republican majority (Holden, 2009).  
Some scientists hope to increase public support for ES cell research by teaching the 
public more about this technology.  Many people are not informed about ES cell research, and 
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the medical potential they have for saving lives.  By carefully explaining the process, perhaps 
more people might change their minds if they discover how many lives could be saved, or once 
they realize that what is being destroyed is a five day hollow ball of cells the size of a dot, not a 
fetus with a growing nervous system (Agnew, 2003).  A healthy debate with church members 
with influence might steer them to change their minds about this issue by helping them see the 
full picture of the research.   
 
Chapter-4 Conclusion 
In this chapter, we have discussed stem cell laws and their significance to stem cell 
research.  For this type of expensive technology, legislation can bar ES cell research from 
receiving tax payers‟ money which then slows progress.  On the other hand, we also emphasized 
that legislation can strongly stimulate the field, as occurred in some countries like Sweden and 
England, and in the Obama led US.  We highlighted the dynamics of the US legislative system, 
showing how some states such as New Jersey, California, Massachusetts, etc. were able to 
override earlier prohibitive federal legislations by offering state bonds to fund this research. We 
discussed the root of this legal opposition to ES cell research, being the moral stand of some 
Christians, especially Catholics, on this issue, and how ethics affects laws.  Finally, we point out 
that although ES cell research is faced with fierce opposition by some, alternative stem cell 
approaches also exist (such as working with adult stem cells or with induced pluripotent cells), 
but those latter cells may not have the full medical potential of ES cells and may be more 
difficult to grow, so the push to fund ES cell research continues. 
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PROJECT CONCLUSIONS 
 
 
 
Both of the authors of this IQP, agree with current US policies that allow new ES cell 
lines to be derived from embryos, because this type of technology will help cure many of the 
world‟s diseases in the future.  Unlike current US policy, we agree that the preferred egg source 
should be women paid to donate their eggs for solely for research purposes, as this type of 
consent helps ensure that the donor indeed wants to donate the eggs for science.  However both 
authors agree that using alternative stem cell sources, such as iPS and adult stem cells, should be 
used whenever possible, and this stance agrees with all major religions and with a majority of the 
public.   Some stem cell applications have already proven to save lives in human patients, 
especially using HSCs to treat leukemia, and using bone marrow stem cells to treat heart attack 
patients.  The countries that both IQP authors agree most strongly with their policies are Israel, 
Switzerland, and Japan, as their policies go beyond those currently allowed in the US, even 
under President Obama.  Within the United States, we applaud the states of  New Jersey, 
Massachusetts, and California for their individual ES cell policies.  The freedom that these 
countries and states give towards ES cell research should go a long way to opening up this 
amazing new regenerative medicine technology in the future. 
 
